GoodFellas Big Board Catalyst and Chart Plays

[EYEBUYSTOX]

PPHM - The real potential in Peregrine is bavituximab oncology, IMO. Of particular importance is the second-line NSCLC indication. The randomized, double-blinded, placebo-controlled Phase II trial is evaluating bavituximab with docetaxel versus docetaxel with placebo in up to 120 second-line NSCLC patients. It will be unblinded by end of Q2 and if results are consistent with past trials it could be a candidate for accelerated approval, especially considering the FDA's recent positive accelerated approval decision with Roche's vismodegib, which was conducted only using a single-arm, multi-center, open-label, 2-cohort trial with 104 patients.

The results and subsequent FDA actions would have huge implications considering the number of other trials PPHM is running for bavituximab oncology in other indications.

In addition, their GBM drug Cotara finished phase II trials months ago with incredible results and a phase III SPA and/or partnership could be announced, literally, any day.

Been lurking on this board for a week or so thanks to a friend's reco and was excited that PPHM was mentioned here as it's my largest holding. Good luck.